Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

Antibody–drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window. DS ‐8201a is a human epidermal growth factor receptor 2 ( HER 2)‐targeting antibody–drug conjugate prepared using a novel linker‐payload system with a potent topoisomerase I inhibitor, exatecan derivative ( DX ‐8951 derivative, DX d). It was effective against trastuzumab emtansine (T‐ DM 1)‐insensitive patient‐derived xenograft models with both high and low HER 2 expression. In this study, the bystander killing effect of DS ‐8201a was evaluated and compared with that of T‐ DM 1. We confirmed that the payload of DS ‐8201a, DX d (1), was highly membrane‐permeable whereas that of T‐ DM 1, Lys‐ SMCC ‐ DM 1, had a low level of permeability. Under a coculture condition of HER 2‐positive KPL ‐4 cells and negative MDA ‐ MB ‐468 cells in vitro , DS ‐8201a killed both cells, whereas T‐ DM 1 and an antibody–drug conjugate with a low permeable payload, anti‐ HER 2‐ DX d (2), did not. In vivo evaluation was carried out using mice inoculated with a mixture of HER 2‐positive NCI ‐N87 cells and HER 2‐negative MDA ‐ MB ‐468‐Luc cells by using an in vivo imaging system. In vivo , DS ‐8201a reduced the luciferase signal of the mice, indicating suppression of the MDA ‐ MB ‐468‐Luc population; however, T‐ DM 1 and anti‐ HER 2‐ DX d (2) did not. Furthermore, it was confirmed that DS ‐8201a was not effective against MDA ‐ MB ‐468‐Luc tumors inoculated at the opposite side of the NCI ‐N87 tumor, suggesting that the bystander killing effect of DS ‐8201a is observed only in cells neighboring HER 2‐positive cells, indicating low concern in terms of systemic toxicity. These results indicated that DS ‐8201a has a potent bystander effect due to a highly membrane‐permeable payload and is beneficial in treating tumors with HER 2 heterogeneity that are unresponsive to T‐ DM 1.